Scott Holmstrom received his doctorate in analytical chemistry from Miami University in 2000 and joined Elanco Animal Health the same year. Dr. Holmstrom has provided chemistry, drug disposition expertise, and significant leadership contributions toward the development and commercialization of drug products for Elanco, including global approvals for Comfortis and Trifexis. Additionally, from 2011 – 2013, he served to integrate the Jannsen Animal Health research and development efforts with those of Elanco.
From 2013-2016, Dr. Holmstrom led global regulatory affairs for Elanco. In this role, he was responsible for shaping the regulatory landscape to enable outcomes for Elanco and their customers, and to ensure that Elanco deliverables are completed in accordance with appropriate regulations and commitments to global regulatory authorities.
In 2016, Scott led Elanco’s efforts for development and execution on late stage external innovation strategies. During this time, Galliprant was in-licensed following the development of specific strategies and execution plans to partner with external companies to commercialize products for Elanco.
Currently, Dr. Holmstrom currently serves as Vice President, Global Product Development, leading Elanco’s global product development efforts, for food and companion and food producing animals, including pharmaceuticals, biopharmaceutics, and vaccines. In this role, he provides the strategic direction for the global development of products through external and internal coordination, governance, and resourcing.